Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the appointment of Ms. Wang Yuzhou as the new securities affairs representative, effective immediately. Ms. Wang brings the necessary expertise and qualifications, including a secretary of the board of directors qualification certificate from the STAR Market of Shanghai Stock Exchange, to fulfill her duties. This appointment is part of the company’s compliance with relevant laws and regulations, ensuring effective management and communication with stakeholders.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology and pharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, particularly in the field of oncology, autoimmune, and infectious diseases.
YTD Price Performance: 38.00%
Average Trading Volume: 2,229,121
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.02B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.